Free accessResearch articleFirst published online 2011-8
OX40 Ligand Levels and High-Sensitivity C-Reactive Protein Levels in Blood from Local Coronary Plaque and the Femoral Artery in Patients with Acute Coronary Syndrome or Stable Angina
OX40 ligand (OX40L) and high-sensitivity C-reactive protein (hs-CRP) play important roles in the pathogenesis of atherosclerosis. In this study, consecutive patients with acute coronary syndrome (ACS; n = 90) or stable angina (SA; n = 40) and healthy control subjects (n = 50) were evaluated to assess plasma OX40L and serum hs-CRP levels in local coronary plaque and the femoral artery. OX40L and hs-CRP levels in the femoral artery were significantly higher in patients with ACS compared with controls. OX40L and hs-CRP levels in local coronary plaque (OX40Lc and hs-CRPc, respectively) were significantly higher in ACS than in SA patients. OX40L and hs-CRP levels were positively correlated with each other and were also correlated with fibrinogen levels. The number of complex lesions was correlated with OX40Lc and hs-CRPc levels. It is concluded that the OX40Lc level was highly sensitive for evaluating the inflammatory response in ACS and elevated levels of OX40Lc may be a valuable predictive marker for increased risk of atherosclerotic progression in ACS patients.
LibbyPRidkerPMMaseriA: Inflammation and atherosclerosis. Circulation2002; 105: 1135–1143.
2.
HanssonGKLibbyP: The immune response in atherosclerosis: A double-edged sword. Nat Rev Immunol2006; 6: 508–519.
3.
TedguiAMallatZ: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev2006; 86: 515–581.
4.
KatritsisDKorovesisSGiazitzoglouE: C-Reactive protein concentrations and angiographic characteristics of coronary lesions. Clin Chem2001; 47: 882–886.
5.
SalehNTornvallP: Serum C-reactive protein response to percutaneous coronary intervention in patients with unstable or stable angina pectoris is associated with the risk of clinical restenosis. Atherosclerosis2007; 195: 374–378.
6.
MuhlesteinJBHorneBDCarlquistJF: Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation2000; 102: 1917–1923.
7.
FigaroMKKritchevskySBResnickHE: Diabetes, inflammation, and functional decline in older adults: findings from the Health, Aging and Body Composition (ABC) study. Diabetes Care2006; 29: 2039–2045.
8.
WangXRiaMKelmensonPM: Positional identification of TNFSF4, encoding OX40 ligand, as a gene that influences atherosclerosis susceptibility. Nat Genet2005; 37: 365–372.
9.
HigginsLMMcDonaldSAWhittleN: Regulation of T cell activation in vitro and in vivo by targeting the OX40–OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol1999; 162: 486–493.
10.
CarboniSAboul-EneinFWaltzingerC: CD134 plays a crucial role in the pathogenesis of EAE and is upregulated in the CNS of patients with multiple sclerosis. J Neuroimmunol2003; 145: 1–11.
11.
NoharaCAkibaHNakajimaA: Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: A critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J Immunol2001; 166: 2108–2115.
12.
van WanrooijEJvan PuijveldeGHde VosP: Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol2007; 27: 204–210.
13.
LiuDMYanJCWangCP: The clinical implications of increased OX40 ligand expression in patients with acute coronary syndrome. Clin Chim Acta2008; 397: 22–26.
14.
LedueTBWeinerDLSipeJD: Analytical evaluation of particle-enhanced immuno-nephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem1998; 35: 745–753.
15.
National Committee for Clinical Laboratory Standards (NCCLS): Procedure for the Determination of Fibrinogen in Plasma, Approved Guideline H30-A. NCCLS: Wayne, PA, 1999: p 99.
16.
GensiniGG: A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol1983; 51: 606.
17.
PatersonDJJefferiesWAGreenJR: Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol1987; 24: 1281–1290.
18.
GodfreyWRFagnoniFFHararaMA: Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med1994; 180: 757–762.
19.
SugamuraKIshiiNWeinbergAD: Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol2004; 4: 420–431.
20.
NorjaSNuutilaLKarhunenPJ: C-reactive protein in vulnerable coronary plaques. J Clin Pathol2007; 60: 545–548.
21.
DanenbergHDSzalaiAJSwaminathanRV: Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation2003; 108: 512–515.
22.
PasceriVWillersonJTYehET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation2000; 102: 2165–2168.
23.
TorzewskiMRistCMortensenRF: C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol2000; 20: 2094–2099.
24.
HaverkateFThompsonSGPykeSD: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet1997; 349: 462–466.
25.
GreenDFoilesNChanC: Elevated fibrinogen levels and subsequent subclinical atherosclerosis: the CARDIA Study. Atherosclerosis2009; 202: 623–631.
26.
Viles-GonzalezJFFusterVBadimonJJ: Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences. Eur Heart J2004; 25: 1197–1207.
